Complement inhibitors for myasthenia gravis in adults

Laura M White; Fiona J Clay; Anne-Marie Forbes; Ryan Yann Shern Keh; James B Lilleker; Jennifer Spillane; Karen Storms; Jon Sussman; Katherine C Dodd

doi:10.1002/14651858.CD016098

Complement inhibitors for myasthenia gravis in adults

Cochrane Database Syst Rev. 2025 Jul 8;7(7):CD016098. doi: 10.1002/14651858.CD016098.

Authors

Laura M White^{1

2}, Fiona J Clay³, Anne-Marie Forbes⁴, Ryan Yann Shern Keh⁵, James B Lilleker^{5

6}, Jennifer Spillane⁷, Karen Storms⁸, Jon Sussman^{5

6}, Katherine C Dodd^{5

6}

Affiliations

¹ Lancaster Medical School, Lancaster University, Lancaster, UK.
² Department of Neurology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
³ Department of Forensic Medicine, Monash University, Southbank, Australia.
⁴ Creative Arts & Health - School of Creative Arts & Media, University of Tasmania, Hobart, Australia.
⁵ Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, Greater Manchester, UK.
⁶ Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK.
⁷ National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
⁸ Library & Knowledge Service, Northern Care Alliance NHS Foundation Trust, Oldham, UK.

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of complement inhibitors for treating myasthenia gravis in adults compared with control treatment (placebo or standard care).

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use
Complement Inactivating Agents* / adverse effects
Complement Inactivating Agents* / therapeutic use
Humans
Myasthenia Gravis* / drug therapy
Randomized Controlled Trials as Topic

Substances

Complement Inactivating Agents
Antibodies, Monoclonal, Humanized